Novel human cytomegalovirus (hcmv) cytotoxic t cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
CA 2451328 A1 · Owner: Elkington, Rebecca Ann · Inventors: Elkington, Rebecca Ann; Khanna, Rajiv; Walker, Susan Jennifer
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides CTL epitope peptides and polyepitope peptides from 14 distinct antigens of human cytomegalovirus (HCMV) that are restricted through HLA the most commonly prevalent class I alleles in different ethnic populations of the world. These epitopes provide an important platform for CTL epitope-based vaccines against HCMV. The present invention further provides vaccine composiitons comprising the subject epitope and polyepitope peptides and methods for vaccination of humans and for the adoptive transfer of HCMVspecific T cells to human subjects. The present invention further provides reagents and methods for determining the HCMV status or level of HCMV-specific …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 26, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 26, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 26, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.